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HaplotypesBackground: Autoimmune hepatitis (AIH) is a chronic inflammatory disease characterized by necrotic
inflammation leading to hepatocyte destruction. The association of human leukocyte antigens (HLA) with
AIH development and onset is not fully elucidated especially in the Tunisian population.
Objectives: The aim of this study was to determine the association of HLA class II alleles and DRB1-DQB1
haplotypes with AIH in Tunisian population.
Patients and Methods: A total of 30 AIH patients and 60 healthy controls were included in the study. HLA
class II typing was performed by Single-specific-primer polymerase chain reaction (PCR-SSP) technique.
Results: Among 13 DRB1 and 5 DQB1 alleles resolved, our results show a positive association of HLA-
DRB1⁄03 (38.3% vs. 21.6%, OR = 2.24, P = 0.028) and negative association of HLA-DRB1⁄11 (3.3% vs.
16.7%, P = 0.019). The analysis of DRB1-DQB1 haplotypes in cases and controls revealed 11-shared hap-
lotypes with a frequency exceeding 1%. HLA-DRB1⁄11-DQB1⁄03 haplotype showed a decreased frequency
in AIH patients (1.6% vs. 15.8%, P = 0.009) and may be considered as an haplotype of resistance to AIH.
Conclusions: To our Knowledge, this is the first study performed to detect the HLA-DRB1 and DQB1 alleles
associated with predisposition to AIH in Tunisian patients. The search for HLA predisposing genes to AIH
may permit an earlier diagnosis allowing a better management and treatment of the disease in order to
avoid liver transplantation.
 2017 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction dence of AIH ranges from 0.67 to 2.0 per 100,000 people per year,Autoimmune hepatitis (AIH) is a chronic inflammatory liver dis-
ease characterized by chronic destructive inflammation within the
liver parenchyma, an interface hepatitis morphology and a female
gender bias [1]. AIH was considered relatively rare, as the inci-with a value of 0.83 per 100,000 in Spain [1]. Its prevalence ranges
from 4.0 to 42.9 per 100,000 people with a high prevalence in
Alaska and Europe [1]. To date, no information was found concern-
ing the incidence of AIH in the North-African populations. The clin-
ical presentations are frequently associated with nonspecific
symptoms such as fatigue, jaundice, nausea, abdominal pain, and
arthralgia [2]. Moreover, elevated transaminase and immunoglob-
ulin G (IgG) levels, and the presence of antibodies characterize the
physiopathology of AIH [3]. Based on the nature of the serum
autoantibodies, clinical behavior and age of presentation, two
types of AIH are described, type 1 and type 2 AIH [4]. The most
prominent antibodies in AIH depend on AIH type. Antinuclear anti-
bodies (ANA) and/or anti-smooth muscle antibodies (SMA) are typ-
ically associated with type 1 AIH, whereas circulating anti-liver/
kidney microsome type1 (LKM1) and/or anti-liver cytosol type 1
(LC-1) antibodies are detected in type 2 AIH [4].
AIH results from the interplay of multiple predisposing causes,
genetic and environmental, but the underlying cause remains
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Barr virus and Cytomegalovirus causes contribute to the AIH devel-
opment [6,7]. Several genes confer susceptibility to AIH; most are
located within the human leukocyte antigen [HLA] region [8].
About 252 genes are expressed in the extended HLA complex,
which span about 7.6 Mb on the short arm of chromosome 6 [9].
These genes are highly polymorphic, especially the HLA class I
and II genes, which encode the peptide-presenting HLA molecules.
The HLA complex is divided into three regions: class I, class II and
class III. The class I region contains the classical HLA-A, HLA-B,
and HLA-C genes that encode the heavy chains of class I molecules.
The class II region consists of DP, DQ and DR subregions, which
contains A and B genes encoding a and b chains, respectively [9].
The class III region contains genes for complement components
(C2, C4, factor B), 21-hydroxylase, tumor necrosis factors (TNFs),
and some others [9].
The association of HLA class II alleles and haplotypes with sus-
ceptibility to AIH was reported in different ethnic groups [10,16].
Indeed, Kekik et al. found a relationship between DRB1⁄03 or
DRB1⁄03:01 alleles possession and AIH susceptibility in Turkish
patients [14]. In Japanese [15,16], Mexican [11] and Korean [17]
populations, AIH risk is associated with DRB1⁄04 allele possession.
Hassan et al. studied the HLA class II distribution in 44 Pakistani
AIH patients and reported a positive association of DRB1⁄14 allele
with AIH development [18]. In Argentinians [12] and Indians [19],
AIH susceptibility was related to DRB1⁄13 allele presence. Several
investigations have also described protective alleles for AIH,
including DRB1⁄08,⁄11 and DRB1⁄13, DQB1⁄03 and DQB1⁄02
[11,14,20,21]. These differences may be due to ethnicity and
genetic backgrounds. The principal susceptibility allele for type 1
AIH in white northern European and American populations is
HLA-DRB1⁄03, and a second, independent risk factor is HLA-
DRB1⁄04 [10,22]. Susceptibility to type 2 AIH was conferred by
the possession of DRB1⁄07, DRB1⁄13 and DQB1⁄02 in Brazilian
patients [20].
To our knowledge, this is the first report studying the associa-
tion of HLA class II alleles with AIH in the Tunisian population
and in North-Africans. The aim of our study was to investigate
the relationship between HLA DRB1/DQB1 alleles and DRB1-
DQB1 haplotypes and AIH risk in Tunisian patients.2. Patients and methods
A total of 30 unrelated patients with definite AIH were recruited
from the gastroenterology department of Military hospital of Tunis,
Charles Nicolle, La Rabta and Habib Thameur Hospitals, between
September 2013 and April 2014. AIH was diagnosed based on
International AIH Group criteria using a scoring calculator
(10–15) [23]. A score of >15 was taken as definite AIH, and 10
as probable AIH. Patients with a score of less than 10 were
excluded from the analysis. Clinical and biological features were
obtained from the medical records of patients. Sixty unrelated
healthy donors were included in our study (47 women and 13
men, mean age 49.6 yrs. ± 7.4) and matched for gender and age
with AIH cases. Study participants have signed an informed con-
sent before the study, and ethics committees approved the study
protocol. The study protocol conforms to the ethical guidelines of
the 1975 Declaration of Helsinki (6th revision, 2008) as reflected
in a priori approval by the institution’s human research committee.2.1. HLA genotyping
Genomic DNA was extracted from lymphocytes separated from
whole blood using a Ficoll–Paque solution (density 1.077 ± 0.001 g/
ml) (24). DNA extraction was performed using QIAamp DNABlood Mini Kit (Qiagen), following the manufacturer’s instruc-
tions. HLA-DRB1 and -DQB1 antigens were detected by Single-
specific-primer polymerase chain reaction (SSP-PCR) technique,
according to Micro SSP Generic HLA class II DNA Typing Trays
DRB1/DQB1 (One lambda). Amplified DNA fragments were ana-
lyzed on 2.5% agarose gel stained with ethidium bromide. HLA
Fusion Software (2005, One lambda) was used to detect specific
DRB1 and DQB1 alleles.
2.2. Statistical analysis
Statistical analysis was performed using SPSS version 20.0 soft-
ware (IBM, Armonk, NY). The frequency of DRB1 and DQB1 alleles
was obtained using Arlequin Software (25); DRB1-DQB1 haplotype
frequencies were determined by the maximum-likelihood method,
through expectation-maximization (EM) algorithm. The compar-
ison of alleles and haplotype frequencies between cases and con-
trols was expressed as P values, odds ratios (ORs), and 95%
confidence intervals (CIs) and was performed by vassarStats
(http://vassarstats.net/). P-Values were corrected using Yates’s cor-
rection, and Fisher’s exact test was applied for low number of sub-
jects with a specific allele or haplotype. A P-value < 0.05 was
considered as statistically significant. Hardy-Weinberg equilibrium
(HWE) was tested at each locus in cases and controls.3. Results
3.1. Clinical and immunological features in AIH patients
Demographic and clinical characteristics of patients are shown
in Table 1. AIH is more frequent in women (86.6%). The mean
age is 52.9 ± 14.1; the mean age at disease onset is 46.2 ± 15.2
and the disease duration is presented as median (IQR), 4.0 (3.0–
7.7). Patients with type 1 AIH are present with a frequency of
93.3% and those with type 2 AIH with 6.6%. The most frequent Clin-
ical presentations are jaundice (80%), asthenia (66.7%), splenome-
galy (46.6%) and Pruritus (43.3%). Specific antibodies were found
in patients’ sera such as ANA (60%) and SMA (53.3%). Three patients
had an infection with cytomegalovirus (CMV) and only one patient
presented Epstein-Barr virus (EBV) infection. (Table 1)
3.2. Distribution of DRB1 and DQB1 alleles
Of the 12 DRB1 allele groups resolved, DRB1⁄03 (38.3%) and
DQB1⁄02 (31.6%) were the most frequent alleles in AIH patients,
whereas DRB1⁄03 (21.6%) and DQB1⁄03 (36.6%) were common in
controls. Our results showed a positive association of DRB1⁄03
allele with AIH risk (38.3% vs. 21.6%, OR (95% CI) = 2.24 (1.14–
4.42), P = 0.028 < 0.05). Conversely, we found a decreased fre-
quency of DRB1⁄11 in cases compared with controls (3.3% vs.
16.7%, OR (95% CI) = 0.17 (0.03–0.76), P = 0.019 < 0.05) (Table 2).
A reanalysis was performed using three genotypes (X/X, DRB1⁄03/
X and DRB1⁄03/DRB1⁄03), where X represents alleles other than
DRB1⁄03. Subjects with the genotype containing two copies of
the DRB1⁄03 alleles (DRB1⁄03/DRB1⁄03) had a high risk of develop-
ing AIH (20% vs. 5%, OR (95% CI) = 5.69 (1.24–26.11),
P = 0.025 < 0.05). On the other hand, the distribution of HLA-
DQB1 alleles in cases and controls revealed a lack of association
with AIH development in Tunisian patients (Table 3).
3.3. Distribution of HLA-DRB1-DQB1 haplotypes
The Table 4 displays the distribution of DRB1-DQB1 haplotypes
in cases and controls. Of 10 haplotypes resolved, DRB1⁄03-
DQB1⁄02 (21.6%) is the most frequent in cases and controls
Table 1
Characteristics of Tunisian autoimmune hepatitis cases and controls.
Parameters Cases1 Controls1 P-Value
Gender, n (%) 0.341
Women 26 (86.6) 47 (78.3)
Age2 52.9 ± 14.1 49.6 ± 7.4 0.237
Smoking, n (%) 0.188
Yes 2 (6.7) 28 (46.6)
Alcohol use, n (%) 0.600
Yes 2 (6.7) 28 (46.6)
Age at onset2 46.2 ± 15.2 NA –
Disease duration3 4.0 (3.0–7.7) NA –





Weight loss 7 (23.3)












EBV infection 1 (3.3)
CMV infection 3 (5.0)
ANA: anti-nuclear antibodies, SMA: Smooth-muscle antibodies, LKM1: anti-Liver/
Kidney Microsomal Antibodies Type 1, SLA: Antibodies against soluble liver antigen,
AMA-M2: anti-mitochondrial antibody-M2, EBV: Epstein - Barr virus, CMV: Cytome-
galovirus, NA: not applicable
1 A total of 30 AIH cases and 60 healthy controls were included.
2 t-Student’s test for the variable ‘‘Age” with normal distribution (mean ± stan-
dard deviation).
3 Variable without normal distribution (median (interquartile range)).
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detected in cases (1.6%) compared with controls (15.8%) (OR
(95% CI) = 0.09 (0.01–0.69), P = 0.009 < 0.05).4. Discussion
AIH is an uncommon chronic hepatitis, which may cause cirrho-
sis and liver failure if it is not treated [26]. These complications
impose a comprehension of AIH physiopathology to find genetic
biomarkers for early AIH diagnosis and management. Many studies
have shown a strong association between the HLA complex genes
and susceptibility to AIH in the different populations.Table 2






DRB1*01 5 8.3 8
DRB1*03 23 38.3 26
DRB1*04 5 8.3 15
DRB1*07 6 10.0 13
DRB1*08 2 3.3 2
DRB1*09 1 1.6 1
DRB1*11 2 3.3 20
DRB1*12 1 1.6 0
DRB1*13 7 11.6 13
DRB1*14 0 0.0 3
DRB1*15 7 11.6 16
DRB1*16 1 1.6 3
N: number of subjects, AIH: autoimmune hepatitis, AF: allele frequency, OR: odds ratio,In our study, we examined the relationship between HLA class II
alleles/haplotypes and AIH susceptibility in Tunisians. The distri-
bution of HLA-DRB1 alleles revealed a positive association of
HLA-DRB1⁄03 with AIH risk in Tunisian patients (P = 0.028). Simi-
lar results were reported in American [10], Argentinian [12],
Venezuelan [13], Turkish [14] patients. In Japan, where DRB1⁄03
is extremely rare in the normal population, susceptibility to AIH
were associated with DRB1⁄04 allele possession [16]. By contrast,
DRB1⁄04 allele is uncommon (9.5%) in Tunisian population [27].
These findings suggest that HLA DRB1⁄03 and HLA DRB1⁄04 genes
may code for HLA molecules that share determinents of suscepti-
bility to AIH. In Pakistani, AIH risk was associated with the pres-
ence of DRB1⁄14 alleles [18], whereas in Argentinians and
Indians, AIH susceptibility was related to DRB1⁄13 allele posses-
sion [12,19].
Several disease-associated HLA molecules would differ by eth-
nicity and genetic background. In fact, a shared amino acid motif
in the antigen-presenting grooves of HLA DR3 and DR4 molecules
coded by HLA DRB1⁄03 and HLA DRB1⁄04 genes respectively may
exist [28]. This critical shared motif is consisted of a six-amino-
acid sequence represented by the code LLEQ-R which is present
predominantly in white North-Americans and North-Europeans
with type I AIH [28]. This sequence found in DRB1⁄03:01 and
DRB1⁄04:01, is located between positions 67 and 72 of the DRb
polypeptide chain of the class II HLA molecule, and lysine K in posi-
tion 71 is the critical determinant of susceptibility [29,30].
These HLA alleles enhance autoimmune activation by enhanc-
ing immunogenicity and influencing the expressed repertoire of T
cells, leading to destruction of self-liver antigens [31].
In addition, our association study shows that HLA-DRB1⁄11
allele is negatively associated with AIH development in Tunisian
patients. DRB1⁄11 allele is common in Tunisian population
(14.4%), which may explain its protective role [27]. Similar results
were found in Iranians [21] and Argentinians [32]. Previous studies
showed that HLA-DRB1⁄08,⁄13 and ⁄15 protects against AIH in
Turkish and Iranians [14,21].
On the other hand, the present association study showed a lack
of association between DQB1 alleles and AIH development in Tuni-
sian patients. Goldberg shared the same results and failed to find
an association of DQB1 alleles with AIH onset [33]. Previous studies
reported a positive association with DQB1⁄04 [13,16,17] and
DQB1⁄06 [11,12] alleles; whereas DQB1⁄03:01 was described as a
protective allele [11,20]. Results on relationship between DQB1
alleles and AIH risk remain controversial due to ethnicity and stud-
ies scale.
This association study of HLA genes and predisposition to AIH
revealed also a protective role of DRB1⁄11-DQB1⁄03 haplotype,
which may prevent AIH onset (1.8% vs. 15.6%, P = 0.009). PreviousStatistical analysis
Patients vs. Controls
OR (95% CI) P-value
6.7 0.762




















AF AF OR (95% CI) P-value
DQB1*02 19 31.6 34 28.3 0.777
DQB1*03 15 25 44 36.6 0.160
DQB1*04 5 8.3 7 5.8 0.537
DQB1*05 8 13.3 15 12.5 0.920
DQB1*06 13 21.6 20 16.6 0.537
N: number of subjects, AIH: autoimmune hepatitis, AF: allele frequency, OR: odds ratio, CI: Confidence interval.
Table 4







n HF n HF OR (CI 95%) P-value
DRB1*01-DQB1*05 5 8.3 6 4.9 0.510
DRB1*03-DQB1*02 11 21.6 24 20.0 1.000
DRB1*04-DQB1*03 4 6.7 12 10.0 0.646
DRB1*07-DQB1*02 5 8.3 10 8.3 0.777
DRB1*11-DQB1*03 1 1.6 19 15.8 0.09 (0.01–0.69) 0.009
DRB1*13-DQB1*06 2 3.3 6 4.9 0.720
DRB1*14-DQB1*05 0 0.0 3 2.5 0.551
DRB1*15-DQB1*06 7 11.6 14 11.6 0.806
DRB1*16-DQB1*04 1 1.6 0 0.0 0.333
DRB1*16-DQB1*05 0 0.0 3 2.5 0.551
N: number of subjects, HF: haplotype frequency, OR: odds ratio, CI: Confidence interval, AIH: autoimmune hepatitis.
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DQB1⁄02:01 in Americans [10] and DRB1⁄15-DQB1⁄06:02 in Japa-
nese [5]. Moreover, this haplotype is common in Tunisian general
population (11.6%), which may explain its protective effect on
AIH in Tunisian patients. Several studies showed a positive associ-
ation of DRB1⁄13-DQB1⁄06 and DRB1⁄04-DQB1⁄04 haplotypes
with AIH risk in Argentinian, Brazilian and Korean patients
[12,17,21]; however, these haplotypes are uncommon in Tunisian
population (4.5%, 3.5%, respectively) [27].
AIH can be associated with many autoimmune diseases, which
share almost the same genetic predisposing genes. Besides overlap
syndromes for primary biliary cirrhosis (PBC) and Primary scleros-
ing cholangitis (PSC), autoimmune thyroiditis are the most com-
mon concurrent disease [30,34]. Other concurrent disorders are
type 1 diabetes mellitus, vitiligo, Sjogren’s syndrome and ulcera-
tive colitis [34]. HLA-DRB1⁄03 or HLA-DRB1⁄04 alleles were found
to be related with PBC in European and Asian populations [35].
Patients with AIH-PBC overlap syndrome presented a predominant
HLA-B8, DRB1⁄03, or DRB1⁄04 alleles similar to AIH [36]. Among
autoimmune thyroid diseases (AITDs), autoimmune hypothy-
roidism has been weakly associated with HLA-DRB1⁄03 or ⁄04 alle-
les [37]. In Tunisia, it has been shown that DRB1⁄03 and DRB1⁄04
are risk alleles for type 1 diabetes, while DRB1⁄11 is a protective
allele [38,39]. AIH susceptibility may be associated with concur-
rent disorders present in AIH patients.
The present study has some strengths, but also limitations.
Questionnaire-based personal interviews were conducted for
assessment for baseline data of studied subjects. Moreover, all sub-
jects included were Arabs. Non-Arab subjects, in particular (native)
Berbers and individuals of European origin were excluded, which
decrease the impact of ethnicity on genetic associations found in
current study. However, technical limitations including high-
resolution typing was not performed for DR3 group and others;
consequently, the amino-acid alignment and association with the
first and the third hyper-variable regions cannot be studied now.
Finally, since our study had a modest sample size, alleles withlow frequency in patients or controls were difficult to assess.
Although this point constitutes a criticism, our results replicate
those reported in other studies.
5. Conclusions
To our knowledge, this is the first report studying the relation-
ship between HLA class II alleles and AIH susceptibility in North-
Africans; our results bring out similarities and differences in HLA
basis from those reported in other countries. We found a positive
association of DRB1⁄03 with AIH onset. By contrast, DRB1⁄11 allele
and DRB1⁄11-DQB1⁄03 haplotype were less frequent among
patients and hence, could be involved in disease resistance.
Large-scale studies and stratified clinical groups can be performed
to verify our findings.
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